Extinct Species Should Stay Extinct
By Ben A. Minteer,
Center for Humans and Nature
| 12. 01. 2014
The Center for Humans and Nature and The Hastings Center have partnered on a series called, How far should we go to bring back lost species? from which this article comes. See more here.
Untitled Document
For a species that’s been dead for a century, the passenger pigeon is having a pretty good year. A flurry of new books, features, and a major documentary has been roughly timed to commemorate the death of “Martha,” the last surviving member of the species that drew her final breath in the Cincinnati Zoo on Sept. 1, 1914. It’s a kind of national elegy for a bird that no one alive today remembers ever seeing, certainly not in the wild, where it was last spotted around the time shovels first broke ground on the New York subway system.
The
bird was a cheap and easily procured source of meat in the 18th and 19th centuries due to its astonishing abundance (once numbering in the billions) and its unfortunate tendency to travel in
massive flocks. Its fate was sealed...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...